Research Analysts Issue Forecasts for Celldex Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:CLDX)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Stock analysts at Lifesci Capital issued their FY2024 EPS estimates for Celldex Therapeutics in a research note issued on Tuesday, May 7th. Lifesci Capital analyst S. Slutsky forecasts that the biopharmaceutical company will post earnings of ($1.90) per share for the year. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.85) per share.

A number of other equities analysts have also recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Friday, March 22nd. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Tuesday. Finally, Guggenheim boosted their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $66.00.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX opened at $41.06 on Thursday. The business’s 50-day moving average is $41.57 and its 200-day moving average is $37.05. Celldex Therapeutics has a 1 year low of $22.11 and a 1 year high of $53.18. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of -14.11 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The company had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $1.20 million.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds have recently made changes to their positions in CLDX. Wellington Management Group LLP lifted its position in shares of Celldex Therapeutics by 5.9% during the third quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company’s stock worth $149,484,000 after acquiring an additional 300,406 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in Celldex Therapeutics during the 4th quarter worth about $994,000. GSA Capital Partners LLP lifted its holdings in Celldex Therapeutics by 192.0% during the 3rd quarter. GSA Capital Partners LLP now owns 44,716 shares of the biopharmaceutical company’s stock worth $1,231,000 after purchasing an additional 29,404 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Celldex Therapeutics by 3.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,547 shares of the biopharmaceutical company’s stock worth $9,950,000 after purchasing an additional 10,818 shares during the period. Finally, Panoramic Investment Advisors LLC purchased a new position in Celldex Therapeutics during the 4th quarter valued at about $258,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.